3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
74
Neoplasm Metastasis
11
Uveal Melanoma
7
Skin Neoplasms
6
Neoplasms
5
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Oligodendroglioma
1
Melanoma, Cutaneous Malignant
1
Melanoma Neoplasms
1
Lung Neoplasms
1
Kidney Neoplasms
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Colonic Neoplasms
1
Carcinoma
1
Carcinoid Tumor
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Advanced Melanoma
1
Interventions
pembrolizumab
8
Nivolumab
4
fludarabine
2
Cyclophosphamide
2
sonidegib
1
obinutuzumab
1
methyl 5-aminolevulinate
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
durvalumab
1
daromun
1
cabozantinib
1
avelumab
1
atezolizumab
1
advexin
1
Tomography, Optical Coherence
1
Therapeutics
1
Taxes
1
Specimen Handling
1
Radiotherapy
1
ProMune
1
Pemetrexed
1
Paclitaxel
1
Oncolytic Virotherapy
1
Mesna
1
Magnetic Resonance Spectroscopy
1
MAPRE1 protein, human
1
Lutetium-177
1
Interleukin-2
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Dacarbazine
×
Dermatologic
×
Clear all
NCT00070642
2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2
Completed
184 enrolled